HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong

Inclusion Criteria: 1. Tested positive for HIV-1 antibody; 2. Aged 18-60, both male and female; 3. BMI (body mass index) in between 18.5 and 24.9 kg/m2 (including upper and lower limits); 4. Received ART for ≥12 months; no drug resistance occurred during this treatment period; 5. Had \<50 copies/ml of plasma HIV RNA for at least (≥) 12 months prior to screening visit; 6. Had ≥350 cells/μL of CD4+ T cells in the past 6 months and \>200 cells/μL of CD4+ T cells before initiation of ART; 7. Adopted contraception method approved by the investigator from screening period until the end of study; 8. Understand the study and voluntarily sign the ICF. Exclusion Criteria: 1. Women who are pregnant or breastfeeding or those who plan to give birth in coming two years (including the subject and his/her spouse); 2. ART has been suspended for more than 2 weeks continuously since ART initiation; 3. Participated in other clinical trials within 24 weeks before the screening visit; 4. Has any opportunistic infections or opportunistic tumors that require systemic treatment within 30 days before being recruited; Has any medical events that the investigator believes will affect the safety and immunogenicity evaluation of the drug; 5. Has a history of autoimmune diseases; Has hypersensitivity to the components of this drug including ICVAX recombinant plasmid, NaCl, Na2HPO4 and NaH2PO4·H2O, and shows severe allergies, such as dyspnea, edema and other symptoms after administration; 6. Received approved vaccines within the past 3 months; 7. Received any blood products, immunoglobulin products, or immunosuppressants within 12 weeks before being recruited; 8. Used interferon, systemic corticosteroids, or other immunosuppressants within the last 3 months (except local application); 9. Positive Hepatitis B surface antigen (HBsAg) within 12 months, or positive Hepatitis C virus antibody (HCV Ab) at screening with confirmatory HCV RNA positive; 10. Has any abnormal laboratory results including: neutrophil \<1×109/L, serum creatinine \> ULN, ALT or AST \>1.5×ULN, hemoglobin \< 11g/dL; 11. Has any medical history or clinical manifestations of any physical or mental illness that may affect the subject's completion of this study; 12. Sensitive to electrical pulse stimulation, such as those who are implanted with pacemaker/ Automatic Implantable Cardioverter Defibrillator (AICD), or those who have wearable medical electronic devices including electrocardiogram; 13. Needle phobia; 14. Have contraindications for intramuscular administration such as confirmed thrombocytopenia, any coagulation dysfunction or currently receiving anticoagulation therapy; 15. The investigator considers that he/she is not suitable to participate in this trial.